177Lu-DOTATATE Therapy in Radioiodine-refractory Differentiated Thyroid Cancer: A Single Center Experience. (October 2018)

• Record Type: Journal Article
• Authors: Roll, Wolfgang; Riemann, Burkhard; Schäfers, Michael; Stegger, Lars; Vrachimis, Alexis
• Is Part Of: Clinical nuclear medicine. Volume 43:Number 10(2018)
• Publication Date: 2018-10
• Subjects: DOTATATE -- PRRT -- RrDTC; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000002219
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Introduction: Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have a rather poor prognosis and are in need of novel treatments. As RrDTCs can in some cases express somatostatin receptors (SSRT), targeting of these receptors by 68 Ga/ 177 Lu-DOTATATE could evolve as a novel theranostic option. Methods: Five RrDTC patients with limited further therapeutic options and documented expression of SSRT using 68 Ga-DOTATATE-PET/CT received 2 to 4 cycles of PRRT with 177 Lu-DOTATATE. Response to therapy was assessed by thyroglobulin (Tg) and morphological and metabolic criteria based on interim and follow-up 68 Ga-DOTATATE-PET/CTs. Analysis was performed on a per-patient basis. Results: In the post-therapy evaluation, only one out of five patients showed a partial response, whereas three patients had a progressive disease. One patient had discordant findings between stable imaging results albeit rising Tg levels. Conclusion: In this case study of five patients, 177 Lu-DOTATATE therapy showed only heterogeneous response and efficacy in RrDTC patients despite good lesional uptake in pre-therapeutic PET.